FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an antibody or its antigen-binding fragment, which binds to human PD-1 (options), isolated nucleic acid encoding the above-mentioned antibody or antigen-binding fragment, an expression vector containing isolated nucleic acid, a host cell producing an antibody or antigen-binding fragment, a composition for enhancing activation of immune cells, and a method for the production of an antibody or antigen-binding fragment.
EFFECT: invention expands the arsenal of agents binding to human PD-1.
35 cl, 6 dwg, 8 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
